Durvalumab and tremelimumab versus doxorubicin in previously untreated patients with advanced or metastatic soft tissue sarcoma: Patient-reported outcomes (PROs) of the randomized phase II MEDISARC study (AIO-STS-0415).

Viktor Gruwald; Barbara Hermes; Armin Tuchscherer; Sebastian Bauer; Rainer Hamacher; Daniel Pink; Lars H. Lindner; Stefan Groeschel; Peter Reichardt; Stephan Richter; Christoph Oing; Marinela Augustin; Martina Margrit Crysandt; Martin Kortuem; Bernd Kasper; Marc Fischer; Philipp Ivanyi

Durvalumab and tremelimumab versus doxorubicin in previously untreated patients with advanced or metastatic soft tissue sarcoma: Patient-reported outcomes (PROs) of the randomized phase II MEDISARC study (AIO-STS-0415).

Viktor Gruwald
, Barbara Hermes
, Armin Tuchscherer
, Sebastian Bauer
, Rainer Hamacher
, Daniel Pink
, Lars H. Lindner
, Stefan Groeschel
, Peter Reichardt
, Stephan Richter
, Christoph Oing
, Marinela Augustin
, Martina Margrit Crysandt
, Martin Kortuem
, Bernd Kasper
, Marc Fischer
, Philipp Ivanyi

Department of Internal Medicine V, Division of Oncology and Hematology

Research output: Contribution to journal › Abstract (Journal) › peer-review

Original language	English
Number of pages	1
Journal	Journal of Clinical Oncology
Volume	42
Issue number	16
Publication status	Published - 1 Jun 2024
Event	Special Clinical Science Symposia - Duration: 29 May 2024 → 29 May 2024

Cite this

Gruwald, V., Hermes, B., Tuchscherer, A., Bauer, S., Hamacher, R., Pink, D., Lindner, L. H., Groeschel, S., Reichardt, P., Richter, S., Oing, C., Augustin, M., Crysandt, M. M., Kortuem, M., Kasper, B., Fischer, M., & Ivanyi, P. (2024). Durvalumab and tremelimumab versus doxorubicin in previously untreated patients with advanced or metastatic soft tissue sarcoma: Patient-reported outcomes (PROs) of the randomized phase II MEDISARC study (AIO-STS-0415). Journal of Clinical Oncology, 42(16).

@article{8f62aa1626f3498caacdb6ffb31953c6,

title = "Durvalumab and tremelimumab versus doxorubicin in previously untreated patients with advanced or metastatic soft tissue sarcoma: Patient-reported outcomes (PROs) of the randomized phase II MEDISARC study (AIO-STS-0415).",

author = "Viktor Gruwald and Barbara Hermes and Armin Tuchscherer and Sebastian Bauer and Rainer Hamacher and Daniel Pink and Lindner, \{Lars H.\} and Stefan Groeschel and Peter Reichardt and Stephan Richter and Christoph Oing and Marinela Augustin and Crysandt, \{Martina Margrit\} and Martin Kortuem and Bernd Kasper and Marc Fischer and Philipp Ivanyi",

year = "2024",

month = jun,

day = "1",

language = "English",

volume = "42",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams \& Wilkins ",

number = "16",

note = "Special Clinical Science Symposia ; Conference date: 29-05-2024 Through 29-05-2024",

}

Gruwald, V, Hermes, B, Tuchscherer, A, Bauer, S, Hamacher, R, Pink, D, Lindner, LH, Groeschel, S, Reichardt, P, Richter, S, Oing, C, Augustin, M, Crysandt, MM, Kortuem, M, Kasper, B, Fischer, M & Ivanyi, P 2024, 'Durvalumab and tremelimumab versus doxorubicin in previously untreated patients with advanced or metastatic soft tissue sarcoma: Patient-reported outcomes (PROs) of the randomized phase II MEDISARC study (AIO-STS-0415).', Journal of Clinical Oncology, vol. 42, no. 16.

Durvalumab and tremelimumab versus doxorubicin in previously untreated patients with advanced or metastatic soft tissue sarcoma: Patient-reported outcomes (PROs) of the randomized phase II MEDISARC study (AIO-STS-0415). / Gruwald, Viktor; Hermes, Barbara; Tuchscherer, Armin et al.
In: Journal of Clinical Oncology, Vol. 42, No. 16, 01.06.2024.

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - Durvalumab and tremelimumab versus doxorubicin in previously untreated patients with advanced or metastatic soft tissue sarcoma

T2 - Special Clinical Science Symposia

AU - Gruwald, Viktor

AU - Hermes, Barbara

AU - Tuchscherer, Armin

AU - Bauer, Sebastian

AU - Hamacher, Rainer

AU - Pink, Daniel

AU - Lindner, Lars H.

AU - Groeschel, Stefan

AU - Reichardt, Peter

AU - Richter, Stephan

AU - Oing, Christoph

AU - Augustin, Marinela

AU - Crysandt, Martina Margrit

AU - Kortuem, Martin

AU - Kasper, Bernd

AU - Fischer, Marc

AU - Ivanyi, Philipp

PY - 2024/6/1

Y1 - 2024/6/1

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pmu_pure&SrcAuth=WosAPI&KeyUT=WOS:001275557402677&DestLinkType=FullRecord&DestApp=WOS_CPL

M3 - Abstract (Journal)

SN - 0732-183X

VL - 42

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 16

Y2 - 29 May 2024 through 29 May 2024

ER -

Durvalumab and tremelimumab versus doxorubicin in previously untreated patients with advanced or metastatic soft tissue sarcoma: Patient-reported outcomes (PROs) of the randomized phase II MEDISARC study (AIO-STS-0415).

Other files and links

Cite this